Novo Nordisk has signed an agreement with Hims & Hers Health that will allow the telehealth provider to offer FDA‑approved versions of Ozempic and Wegovy at self‑pay prices comparable to other digital ...

On February 17, 2026, BLKBRD Asset Management, LP, disclosed it sold out its entire stake in Hims & Hers Health (HIMS +5.89%), an estimated $18.07 million trade based on quarterly ...

Hims & Hers received a flurry of upgrades, though most analysts are opting to stay on the sidelines. Here’s why.

Mahdi and his team found several communication problems. People often didn’t give the chatbots the necessary information to correctly identify the health issue. Conversely, the AI systems often ...

Concerns have focused on the Strait of Hormuz, a narrow waterway off Iran’s coast that a fifth of the world’s oil sails through on a typical day. Iran has threatened to set fire to ships sailing the ...

Amid the company’s efforts to resolve issues raised during an FDA inspection early last year, Novo Nordisk’s operating base in Plainsboro, New Jersey—already the recipient of a recent Form 483—has ...

Check out some of the companies making the biggest moves midday: Hims & Hers Health — Shares of the telehealth company jumped ...

Whether President Trump signaled that he may soon end the military strikes is weighing on the minds of investors, executives and others.

The latest health news features the FDA's move to expedite biosimilar drugs, Roche's trial disappointment, and US-China tensions over drug trade. Hims & Hers partners with Novo Nordisk, increasing its ...

Ozempic maker Novo Nordisk gets another downgrade. The end's in sight for its duopoly status, says TD Cowen. TD Cowen downgraded Novo Nordisk to hold. Novo Nordisk on Tuesday received a broker ...

Novo Nordisk and Hims & Hers have reached a deal that, for now, appears to end their bitter dispute around Hims’ sale of compounded versions of Novo’s blockbuster obesity drug Wegovy.